Aquestive Therapeutics, Inc.

NasdaqGM:AQST Stock Report

Market Cap: US$805.7m

Aquestive Therapeutics Valuation

Is AQST undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AQST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$47.98
Fair Value
85.8% undervalued intrinsic discount
10
Number of Analysts

Below Fair Value: AQST ($6.82) is trading below our estimate of fair value ($47.98)

Significantly Below Fair Value: AQST is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AQST?

Key metric: As AQST is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AQST. This is calculated by dividing AQST's market cap by their current revenue.
What is AQST's PS Ratio?
PS Ratio18.7x
SalesUS$44.13m
Market CapUS$805.68m

Price to Sales Ratio vs Peers

How does AQST's PS Ratio compare to its peers?

The above table shows the PS ratio for AQST vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.6x
PCRX Pacira BioSciences
1.4x7.30%US$955.7m
EYPT EyePoint Pharmaceuticals
20.4x53.65%US$985.5m
SIGA SIGA Technologies
3.3x25.75%US$595.0m
TBPH Theravance Biopharma
9.6x21.72%US$720.2m
AQST Aquestive Therapeutics
18.7x36.99%US$805.7m

Price-To-Sales vs Peers: AQST is expensive based on its Price-To-Sales Ratio (18.7x) compared to the peer average (8.6x).

Price to Sales Ratio vs Industry

How does AQST's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

67 CompaniesPrice / SalesEstimated GrowthMarket Cap
TEVA Teva Pharmaceutical Industries
1.4x2.45%US$22.98b
VTRS Viatris
0.9x1.27%US$12.08b
AMRX Amneal Pharmaceuticals
1.2x7.67%US$3.40b
PRGO Perrigo
0.7x1.67%US$2.84b
AQST 18.7xIndustry Avg. 4.2xNo. of Companies67PS0612182430+
67 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AQST is expensive based on its Price-To-Sales Ratio (18.7x) compared to the US Pharmaceuticals industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is AQST's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AQST PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.7x
Fair PS Ratio8.1x

Price-To-Sales vs Fair Ratio: AQST is expensive based on its Price-To-Sales Ratio (18.7x) compared to the estimated Fair Price-To-Sales Ratio (8.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AQST forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.82
US$9.08
+33.06%
33.24%US$15.00US$4.75n/a10
Oct ’26US$5.88
US$8.78
+49.23%
32.54%US$15.00US$4.75n/a10
Sep ’26US$3.77
US$8.42
+123.25%
34.98%US$15.00US$4.75n/a9
Aug ’26US$3.82
US$8.42
+120.33%
34.98%US$15.00US$4.75n/a9
Jul ’26US$3.40
US$8.42
+147.55%
34.98%US$15.00US$4.75n/a9
Jun ’26US$2.71
US$8.42
+210.58%
34.98%US$15.00US$4.75n/a9
May ’26US$3.00
US$9.86
+228.70%
33.70%US$15.00US$4.75n/a9
Apr ’26US$2.86
US$9.86
+244.79%
33.70%US$15.00US$4.75n/a9
Mar ’26US$2.80
US$10.83
+286.90%
31.08%US$17.00US$5.50n/a9
Feb ’26US$3.02
US$10.83
+258.72%
31.08%US$17.00US$5.50n/a9
Jan ’26US$3.56
US$10.83
+204.31%
31.08%US$17.00US$5.50n/a9
Dec ’25US$5.09
US$10.06
+97.69%
27.04%US$15.00US$5.50n/a8
Nov ’25US$5.52
US$9.56
+73.23%
31.31%US$15.00US$5.50US$6.828
Oct ’25US$4.76
US$9.44
+98.27%
30.37%US$15.00US$5.50US$5.888
Sep ’25US$4.53
US$8.81
+94.54%
30.55%US$15.00US$5.50US$3.778
Aug ’25US$3.59
US$8.56
+138.51%
25.02%US$13.00US$5.50US$3.828
Jul ’25US$2.45
US$8.61
+251.47%
23.51%US$13.00US$5.50US$3.409
Jun ’25US$2.88
US$8.61
+199.00%
23.51%US$13.00US$5.50US$2.719
May ’25US$3.37
US$9.13
+171.17%
20.09%US$13.00US$7.00US$3.008
Apr ’25US$4.13
US$8.86
+114.46%
18.53%US$12.00US$7.00US$2.867
Mar ’25US$4.24
US$6.33
+49.37%
37.22%US$10.00US$3.00US$2.806
Feb ’25US$2.67
US$6.33
+137.20%
37.22%US$10.00US$3.00US$3.026
Jan ’25US$2.02
US$6.33
+213.53%
37.22%US$10.00US$3.00US$3.566
Dec ’24US$2.39
US$6.33
+164.99%
37.22%US$10.00US$3.00US$5.096
Nov ’24US$1.54
US$6.17
+300.43%
39.07%US$10.00US$3.00US$5.526
US$9.08
Fair Value
24.8% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/31 13:25
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aquestive Therapeutics, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Gary NachmanBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.